ATC code J

Pharmaceutical drug classification
ATC code J: Antiinfectives for systemic use
  • J01 Antibacterials for systemic use
  • J02 Antimycotics for systemic use
  • J04 Antimycobacterials
  • J05 Antivirals for systemic use
Human only
  • J06 Immune sera and immunoglobulins
  • J07 Vaccines
ATCvet only
  • QJ51 Antibacterials for intramammary use
  • QJ54 Antimycobacterials for intramammary use
Other ATC codes

ATC code J Antiinfectives for systemic use is a section of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.[1][2][3][4]

Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QJ.[5] ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list.
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.

See also

  • Immune sera, immunoglobulins and vaccines for veterinary use are in the ATCvet group QI.

References

  1. ^ "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020.
  2. ^ World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.
  3. ^ "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.
  4. ^ "ATC/DDD Index 2022: code J". WHO Collaborating Centre for Drug Statistics Methodology.
  5. ^ "ATCvet Index 2022: code QJ". WHO Collaborating Centre for Drug Statistics Methodology.
  • v
  • t
  • e
Major chemical drug groups – based upon the Anatomical Therapeutic Chemical Classification System
gastrointestinal tract
/ metabolism (A)blood and blood
forming organs (B)cardiovascular
system (C)skin (D)genitourinary
system (G)endocrine
system (H)infections and
infestations (J, P, QI)malignant disease
(L01–L02)immune disease
(L03–L04)muscles, bones,
and joints (M)brain and
nervous system (N)respiratory
system (R)sensory organs (S)other ATC (V)
  •  Drugs
  • Pharmacological classification systems
  • ATC codes
  •  Medicine portal
  • v
  • t
  • e
30S
Aminoglycosides
(initiation inhibitors)
-mycin (Streptomyces)
-micin (Micromonospora)
other
Tetracycline antibiotics
(tRNA binding)
Tetracyclines
Glycylcyclines
50S
Oxazolidinone
(initiation inhibitors)
Peptidyl transferase
Amphenicols
Pleuromutilins
MLS (transpeptidation/translocation)
Macrolides
Ketolides
Lincosamides
Streptogramins
EF-G
Steroid antibacterials
  • v
  • t
  • e
Beta-lactams
(inhibit synthesis
of peptidoglycan
layer of bacterial
cell wall by binding
to and inhibiting
PBPs, a group of
D-alanyl-D-alanine
transpeptidases)
Penicillins (Penams)
Narrow
spectrum
β-lactamase sensitive
(1st generation)
β-lactamase resistant
(2nd generation)
Extended
spectrum
Aminopenicillins (3rd generation)
Carboxypenicillins (4th generation)
Ureidopenicillins (4th generation)
Other
Carbapenems / Penems
Cephems
Cephalosporins
Cephamycins
Carbacephems
1st generation
2nd generation
3rd generation
4th generation
5th generation
Siderophore
Veterinary
Monobactams
β-lactamase inhibitors
Combinations
Polypeptides
Glycopeptides
Lipoglycopeptides
Lipopeptides
Polymyxins
Other
  • Inhibits PG elongation and crosslinking: Ramoplanin§
Intracellular
Other
  • v
  • t
  • e
Antifolates
(inhibit bacterial
purine metabolism,
thereby inhibiting
DNA and RNA
synthesis)
DHFR inhibitor
Sulfonamides
(DHPS inhibitor)
Short-acting
Intermediate-acting
Long-acting
Other/ungrouped
Combinations
Other DHPS inhibitors
Quinolones
(inhibit bacterial
topoisomerase
and/or DNA gyrase,
thereby inhibiting
DNA replication)
1st generation
Fluoroquinolones
2nd generation
3rd generation
4th generation
Veterinary
Newer non-fluorinated
Related (DG)
Anaerobic DNA
inhibitors
Nitroimidazole derivatives
Nitrofuran derivatives
RNA synthesis
Rifamycins/
RNA polymerase
Lipiarmycins
  • v
  • t
  • e
Wall/
membrane
Ergosterol
inhibitors
Azoles (lanosterol 14α-
demethylase inhibitors)
Imidazoles
Triazoles
Thiazoles
Polyene antimycotics
(ergosterol binding)
Squalene monooxygenase
inhibitors
Allylamines
Benzylamines
Others
β-glucan synthase
inhibitors
Intracellular
Pyrimidine analogues/
thymidylate synthase inhibitors
Mitotic inhibitors
Aminoacyl tRNA synthetase inhibitors
Others
  • v
  • t
  • e
Nucleic acid inhibitor
Rifamycins/
RNA polymerase inhibitor
Antifolates/DSI
ASA
Topoisomerase inhibitors/
quinolones
Protein synthesis inhibitor
Aminoglycosides
Oxazolidone
Polypeptide antibiotics
Cell envelope antibiotic
Peptidoglycan layer
Arabinogalactan layer
Mycolic acid layer
Other/unknown
Combinations
  • v
  • t
  • e
DNA virus antivirals (primarily J05, also S01AD and D06BB)
Baltimore I
Herpesvirus
DNA-synthesis
inhibitor
TK activated
Purine analogue
Pyrimidine analogue
Not TK activated
Other
HPV/MC
Vaccinia
Poxviridae
Hepatitis B (VII)
Multiple/general
Nucleic acid inhibitors
Interferon
Multiple/unknown
  • v
  • t
  • e
RNA virus antivirals (primarily J05, also S01AD and D06BB)
Hepatitis C
NS3/4A protease inhibitors (–previr)
NS5A inhibitors (–asvir)
NS5B RNA polymerase inhibitors (–buvir)
Combination drugs
Hepatitis D
Picornavirus
Anti-influenza agents
Multiple/general
Interferon
3CL protease inhibitors (–trelvir)
RNA pol inhibitors
Multiple/Unknown/Other
  • v
  • t
  • e
Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)
Capsid inhibitors
Entry/fusion inhibitors
(Discovery and development)
Integrase inhibitors
(Integrase strand transfer inhibitors (INSTI))
Maturation inhibitors
Protease Inhibitors (PI)
(Discovery and development)
1st generation
2nd generation
Reverse-transcriptase
inhibitors (RTIs)
Nucleoside and
nucleotide (NRTI)
Non-nucleoside (NNRTI)
(Discovery and development)
1st generation
2nd generation
Combined formulations
Pharmacokinetic boosters
Experimental agents
Uncoating inhibitors
Transcription inhibitors
  • Tat antagonists
Translation inhibitors
BNAbs
Other
Failed agents
°DHHS recommended initial regimen options. Formerly or rarely used agent.
  • v
  • t
  • e
Development
Classes
Administration
Vaccines
Bacterial
Viral
Protozoan
Helminthiasis
Other
Inventors/
researchers
Controversy
Related